Skip to content
PreclinicalResearch compoundModerate evidence

NSI‑189

Experimental compound studied for depression that may stimulate new nerve cells; not proven in humans.

NootropicMood SupportNeurotrophinsMood SupportNeuroprotectionBDNFBDNF

Pharmacology

ClassMood Support · Neuroprotection · BDNF
Primary targetTLX / NR2E1 nuclear receptor (potent agonist)
Targets4 receptor targets
Half-life17-20 h
Onset1-2 weeks (subjective), 4-6 weeks (plateau)
EvidenceModerate evidence
Affected systemsBDNF

Contents

DETAILED OVERVIEW

What is NSI-189?

NSI-189 is an experimental compound studied mainly as a treatment for depression. It is not an approved medicine: in the United States it is at the clinical trial stage, and in the EU it counts as a research chemical. It has been studied mostly in animals, and its effect is not proven in humans.

It is thought to stimulate the formation of new nerve cells in the hippocampus, a brain area linked to memory, but its exact mechanism is unclear. In a study of people with depression it did not produce a significant improvement on the main outcome measure, only on secondary measures and the patients' own reports. It may cause early irritability, insomnia and headache, and its long-term safety is unknown. In bipolar disorder it carries a risk of mania, in active psychosis it may worsen symptoms, and together with certain antidepressants it carries a risk of serotonin syndrome (a dangerous excess of serotonin). There are no safety data for pregnancy or breastfeeding.

Mechanism

Hippocampal neurogenesis

Half-life

17-20 hours

Onset

1-2 weeks (subjective), 4-6 weeks (plateau)

Legal status

USA research, FDA Phase 2

Receptor profile

  • TLX / NR2E1 nuclear receptorStrong
  • Hippocampal neurogenesisStrong
  • BDNFModerate
  • PI3K/Akt/mTOR signalingModerate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Early irritability, mood agitation (typically in the first week)
  • Insomnia, disrupted sleep (avoid late-evening dosing)
  • Headache, mild anxiety (anecdotal reports)
  • Higher doses (80+ mg) bring more side effects, not stronger benefit (bell-shaped curve)
  • Limited human safety data, full side-effect spectrum unknown
  • Long half-life (17-20 h) gives cumulative effect, steady state in 4-5 days

Contraindications · 6

  • Pregnancy, breastfeeding (no clinical safety data)
  • Avoid combining with MAOIs (preclinically untested monoaminergic interaction)
  • SSRI/SNRI combination only under medical supervision (serotonin syndrome risk)
  • Bipolar spectrum: mania risk, medical monitoring required
  • Active psychotic disorder (neurogenesis-inducing mechanism may worsen symptoms)
  • Caution with CNS depressants (alcohol, benzodiazepines); not FDA-approved, unknown long-term safety

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

NSI-189 is an experimental, still-researched substance that has mainly been studied in clinical trials for depression, with the unusual feature that it is said to stimulate regrowth in the brain's memory-related region, the hippocampus. Trials have observed benefits for mood as well as cognitive functions like memory and learning, and interestingly the effects may persist after stopping the treatment, since the change is described as structural rather than immediate. Because this is still a substance in development rather than an approved medicine, human experience with it remains limited to clinical trial settings.

Telegram

Have a question about NSI‑189?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC22H30N4O
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.